drugset / Trial / NCT01030406
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Phase 2
Completed
49 enrolled
Acura Pharmaceuticals Inc.
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niacin | Small molecule | 240 mg | Oral |
| Subject | Niacin | Small molecule | 480 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 40 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 80 mg | Oral |